KPV
A short peptide fragment associated with gut-barrier, inflammatory, and tissue-soothing discussions in the peptide market.
Also appears in: Immune · Dermal
What has the price actually done?
Daily, exact-comparability offers. Discounts use the terms known on each historical date.
How this history is calculated
Effective price per mg uses an active dated override first, then the row-level historical discount, then the vendor default from the same Git revision. Aggregate chart points include exact-comparability offers only. Missing observations remain gaps; the series does not interpolate across unavailable offers or absent snapshots.
Let the market come to you.
Watch the best market price or one vendor. Get one email when KPV crosses your target, drops, or sets a new tracked low—without daily noise.
This name primarily lives in the research market and should not be read like an approved pharmaceutical product.
Primary research area: Tissue repair. Also surfaces under Immune · Dermal for browsing and discovery.
No major aliases are tracked for this profile yet.
No FDA label signal · 0 trials · 133 PubMed results
Current evidence for KPV is limited to laboratory or animal studies — there are no name-matched human trials with reported results. Any claims about effects in people are not yet backed by clinical data.
KPV has no clinical trials that name it and 133 PubMed-indexed publications and is not FDA-approved. Current evidence is preclinical or mechanistic.
Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.
Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-09-08 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →
What KPV is
KPV is a short peptide fragment that often appears in gut-health, inflammation, and repair-oriented product lines. It is especially common in blends marketed around recovery or skin support.
Why it matters
KPV shows how the recovery category extends beyond tendon-and-muscle peptides into gut and inflammatory signaling.
Regulatory context
KPV is not FDA approved in the United States and is best treated as a research-market peptide.
Practical reading note
If a vendor frames KPV as a cure-all, that is usually a sign to slow down and separate plausible mechanistic interest from broad consumer claims.